Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.google.com/search?q=charlie+maxwell+oil+analyst&ei=UO6mWujgG4nWjwPT-o_ADA&start=10&sa=N&biw=1288&bih=677 ~~~~~~~ member mark me I will mark you back , ok
name sounds familiar
Do you know CHARLIE MAXWELL from the old COPYTELE days?
Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine
DECEMBER 21, 2020
https://fox8.com/news/fda-clears-way-for-cleveland-clinics-groundbreaking-breast-cancer-vaccine/
Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing
Mon, December 14, 2020, 9:00 AM EST
SAN JOSE, Calif., Dec. 14, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem GmbH have verified that one of their recently discovered compounds is similar in potency to remdesivir, the only approved anti-viral drug against SARS-Cov-2. As previously announced, Anixa and OntoChem had identified multiple compounds that could disrupt the function of a viral enzyme called an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15).
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Remdesivir is a pro-drug whose metabolite interferes with a SARS-CoV-2 enzyme, RNA-Polymerase. Similarly, Anixa's lead compound interferes with the function of another SARS-Cov-2 enzyme, NSP-15, the noted endoribonuclease. NSP-15 is needed by the virus to process its RNA, it's genetic code. Interfering with this enzyme makes it impossible for the virus to replicate. The comparison of potency with remdesivir was conducted in a human cell line by measuring IC50 in an assay known as a plaque reduction assay. IC50 is a standard measure of the amount of drug needed to inhibit replication (production of plaques) of the virus by 50%.
"Through medicinal chemistry modifications we feel we can improve this compound's potency even more. In the next few months, we will be testing the in vivo potency of this compound in an animal study," stated Dr. Amit Kumar, President and CEO of Anixa. "While we are all excited about the development of Covid-19 vaccines, we still do not know how long immunity is conferred by vaccination, nor do we know what will happen should the virus's spike protein mutate, like the flu virus."
Dr. Kumar added, "Therapies such as remdesivir, monoclonal antibodies and dexamethasone are required to be administered by injection in a hospital setting. Our compound, should it reach the market, is expected to be taken as a pill by patients infected by SARS-CoV-2, to eliminate the disease before symptoms require hospitalization. At the current time, there are no Covid-19 medicines that can be taken in an outpatient setting. Accordingly, we feel there is a need for inexpensive, orally administrable medicines for this viral infection."
Dr. Lutz Weber, CEO of OntoChem, stated, "Our team includes Anixa Biosciences, my team at OntoChem, a team of organic synthetic chemists in Austria and a national laboratory in Italy with a biosafety level 3 (BSL-3) laboratory and capabilities for animal studies. We began this project with Anixa from scratch and are pleased that our collaboration has led to a very potent anti-viral compound. While we take our first compound into proof-of concept animal studies, we will continue synthesizing and testing additional promising compounds."
Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine
Mon, November 23, 2020, 8:30 AM EST
SAN JOSE, Calif., Nov. 23, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its prophylactic breast cancer vaccine has been filed with the U.S. Food and Drug Administration.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
This vaccine technology was invented by a research team from Cleveland Clinic, led by Dr. Vincent Tuohy, the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Anixa has a worldwide, exclusive license to this technology.
The technology takes advantage of self-proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein, alpha-lactalbumin, is expressed only in the mammary glands during lactation and then disappears once lactation ceases. Dr. Tuohy discovered that this protein is abnormally expressed again when a woman contracts breast cancer, especially Triple Negative Breast Cancer (TNBC), the most deadly form of this disease. Dr. Tuohy postulated that if women could be immunized against this protein after their childbearing years, the immune system could be trained to destroy cancer cells as they arise while ignoring normal cells that no longer express this protein, thus making it difficult for the cancer to gain critical mass. Early studies to test this theory demonstrated highly significant prevention of breast cancer in animal models.
The technology is being developed at Cleveland Clinic with funding from the U.S. Department of Defense. The funding is expected to enable completion of two Phase 1 clinical trials.
"This has the potential to be a paradigm-shifting clinical study," said Dr. Tuohy. "If our data demonstrate results similar to the pre-clinical studies, this vaccine could have a significant impact on breast cancer, the most common malignancy in women. Furthermore, the way we think about controlling breast cancer may completely change."
"We look forward to moving this novel technology into the clinical stage of development," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. "If the data in humans is comparable to the data in animals, Dr. Tuohy's 'retired' protein hypothesis will usher in a new way to prevent breast cancer, as well as other types of tumors."
"This initial clinical trial will be with women who have been diagnosed with high-risk early stage TNBC and are receiving standard of care at Cleveland Clinic," said Dr. G. Thomas Budd, Department of Medical Oncology at the Taussig Cancer Center at Cleveland Clinic, and the Clinical Investigator who will be conducting the trial. "We look forward to commencing the Phase 1 clinical trial and evaluating these patients."
Anixa’s Breast Cancer Vaccine; A Conversation With Dr. Vince Tuohy
By
Daniel Carlson, Tailwinds research
-
September 22, 2020
This week I had the opportunity to speak with Dr. Vincent Tuohy of the Cleveland Clinic. Dr. Tuohy is the inventor and research leader of the breast cancer vaccine program that has been partnered with Anixa. The program has had very successful animal trials and is in the final stages of prepping for an IND filing. It’s often rare for Key Opinion Leaders (KOLs) to talk to non-scientists, but Dr. Amit Kumar of Anixa helped enable this conversation in anticipation of the IND filing, and the upcoming month of October, which is Breast Cancer awareness month.
I left the conversation very excited about the product, its prospects with the FDA and the implications for Anixa. Here is my summary of the key portions of the conversation (I have bolded what I believe are the highlights), followed by my thoughts on the program.
Tailwinds Research – how does this technology work and why do you think it will be successful?
Dr. Tuohy – In the area of vaccination against infectious disease, scientists have been very successful in battling many diseases like small pox, polio and others. The cancer vaccine story is rife with many failures, and there are many reasons for this. We designed a program that takes lots of lessons from the success of childhood vaccines, the failures of cancer vaccines, and an understanding of autoimmunity. Our program identified an antigen, or target for the immune system, that is no longer around in adult women who are not lactating, but shows up in the breast when cancer develops. We also use a very powerful adjuvant, which helps the immune system mount a strong response to the antigen. Based on my background and understanding of how the immune system can sometimes destroy organs, I identified an approach for the immune system to destroy not the organ but the cancer in that organ. The studies in animals showed a powerful effect, and now this is the most powerful immune response that I could think of creating.
And we’re on the verge now of being able to test it in humans. We’ve generated the vaccine, the adjuvant. We’re submitting the application to the FDA shortly within the current month. And we think that we should be able to start phase one trials for dosage and safety by the beginning of this coming year
Tailwinds Research – What gives you comfort that the FDA will accept an IND for your cancer vaccine?
Dr. Tuohy – We’ve already had two pre-IND meetings with the FDA and we’ve discussed our plans with them extensively, really, I mean, in great detail. And they have indicated very clearly what they wanted from us. And we spent the last, oh, I would say over a year now, dealing with everything that they told us to do. They always have the right to ask for more, but we are hopeful that we have addressed everything they want.
Tailwinds Research – what kind of data do you expect to get out of a Phase one trial? And what specific end points are you using in this trial?
Dr. Tuohy – Well, phase one is a classic phase one. It’s a dosage and safety trial. So, we will increase the dosage until we reach toxicity and then pull back until we have a dose that gives us an effective immune response. We do not expect much toxicity because the protein target is not there in women who are not lactating or who don’t have cancer.
And so far in our toxicology studies and our immunogenicity studies, we haven’t seen anything that is out of the ordinary in terms of the common side effects that you get from any cancer vaccine.
Besides safety we will be monitoring the patients to see if our vaccine has induced antibodies that target our protein and the T-cells that target the protein. These antibodies and T-cells will be measured before vaccination , so if they are there after vaccination, we know our vaccine induced their creation and the vaccine is doing what we want.
We hope we can finish the first trial within 2021, then we will follow up with the second trial.
Tailwinds Research – you did mention that Phase I studies are funded by the government. Do you think there’s any possible possibility, based on success there, that the government will fund phase II studies?
Dr. Tuohy – I think it’s definitely possible if we can show that we have a very active immune response, which I’m very confident about. This is not a weak vaccine. This is the most powerful vaccine I could think of making. And I have no doubts that we’re going to get there.
This is not a critique, but a lot of people are down on cancer vaccines because they haven’t worked and they haven’t worked, in my opinion, because, A, they have been using cryptic antigens that have no high affinity T cell clones in the repertoire available to react to them. And B, they’re not using aggressive Type 1 and Type 17 adjuvants to induce a very, very powerful immune response.
So, I’m confident that we can get a very good immune response. I think if we show the results that I anticipate, there is likely to be a lot of interest in funding to continue the development of the vaccine. The US spends over $40 BB dollars annually for breast cancer. So, yes, I do think the government would be interested when they look at just the finances.
At Tailwinds, as investors, we remain very optimistic about Anixa’s breast cancer vaccine program. There are several key points to keep in mind here when one looks at what Anixa is doing.
• The Cleveland Clinic is a world-class research organization. They are at the top of the pyramid along with others like the Mayo Clinic and Sloan Kettering. It’s easy to dismiss Anixa as a micro-cap company with few employees and a small budget, but their strategy of working with the best possible partners gives them a depth and breadth of research that extends far beyond the normal reach for a company their size.
• The market for vaccines is massive. If this product works, you’re looking at a multi-billion-dollar opportunity. (For a case in point, just look at what happened to Moderna stock recently) We will know if there is a positive response sometime in 2021. So, in less than one year, we’ll know if this $60M market cap company could have a billion-dollar program on their hands.
• For further proof of the market size here in Triple Negative Breast Cancer, look at Gilead’s purchase of Immunomedics. They paid $21 billion for a drug that has only increased survival from 1 ½ months to 5 ½ months. Once again, IF the vaccine works, this is a big opportunity.
The management of Anixa has continually bought shares in the open market, which demonstrates not only their belief in the product pipeline, but the deeply discounted valuation. The risk/reward here seems incredible to me.
By the end of next year, Anixa will have two potential blockbuster programs returning human data. Due to the unique nature of their business model, these programs aren’t costing an arm and a leg. Tremendous upside from a small investment…it’s a great business model.
Anixa is on the cusp of going from pre-clinical to having two simultaneous in-human trials. The first step is an accepted IND submission. We are only a handful of days away from the first IND being submitted and less than two months from learning if it is accepted. Exciting times ahead.
Tailwinds' Disclaimers & Disclosures: Tailwinds may have been compensated for writing this article. For a full list of disclaimers and disclosures, please visit http://tailwindsresearch.com/disclaimer/.
https://tailwindsresearch.com/2020/09/anixas-breast-cancer-vaccine-a-conversation-with-dr-vince-tuohy/
Anyone here? Stocks been steadily moving up on increasing volume.
Seems like news is coming??
Potential Covid-19 Drugs for Testing in Biological Assays
By Daniel Carlson -June 1, 2020
Tailwinds’ Take: great first steps. Moving successfully through biological assays and into animal testing is the big value driver. Hopefully we start hearing some of those results in the near future.
SAN JOSE, Calif., June 1, 2020 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 (https://ir.anixa.com/press-releases/detail/947/) and announced discovery of its first potential Covid-19 candidate two weeks later on May 4, 2020.
The initial phase of this program was designed to screen approximately 1.2 billion chemical compounds, utilizing in silico methods, against two specific enzymes of SARS-CoV-2. As the computer-based screening identified potential compounds, they would be synthesized and tested in biological assays to evaluate their potency as predicted by the molecular modeling algorithms. Should the biological activity be verified, the compounds will be tested in animal studies to further evaluate their candidacy as Covid-19 therapeutics. Assuming animal studies are successful, the compound or compounds can be readied for human testing.
Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, “When we announced our strategic collaboration with OntoChem, we committed to providing frequent updates regarding the progress of our research, because Covid-19 is such an acute public health and economic problem. Therefore, we are pleased to announce that since identifying a lead molecule, we have further identified three similar analog compounds. These molecules target a viral protein, an endoribonuclease, that helps the virus process its genetic material during viral replication. Before the endoribonuclease can function properly, it needs to interact with a human protein in the infected human cell. Our in silico molecular modeling indicates that any of these four molecules might disrupt the ability of the viral endoribonuclease to interact with the human protein. If this is confirmed in our biological testing, we believe the molecules should inhibit the viral replication process and retard the infection.”
Dr. Lutz Weber, President and CEO of OntoChem, stated, “While we continue to screen the full libraries of compounds, we are pleased that our efforts have rapidly identified four compounds. These compounds have been synthesized and we are now engaged in testing these compounds in biological assays to verify the efficacy that was predicted in silico.”
Dr. Kumar continued, “We hope to provide an update regarding the biological testing as soon as we have completed the tests. One of the tests is a viral replication test that utilizes active SARS-CoV-2 virus. This test must be performed in a Biological Safety Level 3 laboratory to maintain safety and confinement.” Dr. Kumar continued, “While we are making incredibly rapid progress in our discovery efforts and hope to continue the pace of research, it’s important to note that we are in the early stages of the program.”
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa’s therapeutic portfolio includes a cancer vaccine technology focused on the immunization against a-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company’s diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body’s immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
https://tailwindsresearch.com/2020/06/anixa-biosciences-and-ontochem-have-synthesized-four-potential-covid-19-drugs-for-testing-in-biological-assays/
$ANIX Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays
https://www.prnewswire.com/news-releases/anixa-biosciences-and-ontochem-have-synthesized-four-potential-covid-19-drugs-for-testing-in-biological-assays-301068026.html
Back to the $4 PT
$ANIX Anixa Biosciences (Nasdaq:ANIX) Looking Forward to Initiating Human Trials with Breast Cancer Vaccine by End of 2020
http://www.releasewire.com/press-releases/anixa-biosciences-nasdaqanix-looking-forward-initiating-human-trials-1292707.htm#.Xs_VIVYAvfk.twitter
Interesting presentation.
ANIX
$ANIX CEO Amit Kumar Discusses How The Pandemic Has Impacted The Company And Finding A Cure For Covid-19" on TD Ameritrade Network.
https://tdameritradenetwork.com/video/rB4AoXHUFCyBceaKZaQFuw
Breakout coming today
$ANIX Target $4
ALL ABOARD?
Wow impressive. Going higher I hope
Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program
PR Newswire PR Newswire•February 12, 2020
SAN JOSE, Calif., Feb. 12, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that the research team lead by Dr. Jose Conejo-Garcia, Chair of the Department of Immunology at Moffitt Cancer Center, Anixa's development partner, has completed and validated the reformulation of the viral vector necessary for its CAR-T program.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
Last year, Anixa announced, that in order to improve the potential efficacy of its CAR-T therapy, it would reformulate the viral vector used to infect and engineer each individual patient's T-cells. The purpose was to increase the expression level of the Follicle Stimulating Hormone (FSH) on the engineered, autologous T-cells. With the successful viral vector reformulation, verification and validation, the new viral formulation is now being manufactured under Good Manufacturing Practice (GMP) conditions. This manufacturing process is expected to take approximately three months and Anixa and Moffitt remain on track to file the Investigational New Drug (IND) application in 2020.
CAR-T therapy requires the extraction and isolation of an individual's T-cells, followed by engineering these cells to enable them to more effectively kill cancer. These cells are then expanded and reinfused into the patient. Engineering these cells is performed by using a virus that itself has been engineered. The engineered virus initially infects the T-cells. Successive to infection, the virus induces the cellular machinery of the patient's T-cell to create on its surface, the "homing missiles" which in the case of Anixa's therapy are FSH molecules. It is expected that a T-cell with more FSH on the surface will be more effective at targeting ovarian cancer.
Dr. Amit Kumar, President and CEO of Anixa stated, "We are pleased to have completed this first milestone in our development program and remain confident in our previously stated development timeline."
"Our laboratory completed the reformulation of the viral vector, and we have demonstrated its ability to increase the concentration of FSH on the surface of transformed human T-cells. We expect the increased expression of FSH to provide better efficacy of our drug for ovarian cancer patients. We are looking forward to taking this therapy into the clinic as soon as possible," stated Dr. Conejo-Garcia.
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against a-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Anixa Biosciences Provides Update on CAR-T Program
PR Newswire PR Newswire•December 13, 2019
SAN JOSE, Calif., Dec. 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced an update regarding the chimeric antigen receptor T-cell (CAR-T) technology it is developing with its partner, Moffitt Cancer Center.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
Experimental results reported from the laboratory of Dr. Jose Conejo-Garcia, the inventor of Anixa's CAR-T technology and the Chair of the Department of Immunology at Moffitt, indicate that the potential efficacy of this technology as a treatment for ovarian cancer could be greatly improved through additional genetic engineering.
CAR-T therapy begins with the extraction and isolation of T-cells from individual cancer patients. A viral vector is then used to transform these T-cells to produce on their surface a molecule that enables the cell, once re-infused into the patient, to find cancer cells and kill them. With Anixa's CAR-T therapy, the T-cells are transformed to express on their surface, the follicle stimulating hormone (FSH), which targets cells that are expressing follicle stimulating hormone receptor (FSHR).
Dr. Conejo-Garcia's recent experimental results indicate that with additional engineering, the transformed cells produced by the viral vector currently being used could express much higher levels of FSH, enabling a more potent cancer killer. In order to increase the potency of the transformed T-cells, researchers at Moffitt will create an improved viral vector and verify experimentally that it will result in a more powerful cancer therapy. As a result, the decision has been made to optimize the therapy and file an Investigational New Drug (IND) application with the US. Food and Drug Administration in the future. This optimization work may take an additional year, resulting in the filing of the IND in late 2020, with clinical trials to commence in 2021.
Dr. Amit Kumar, President and CEO of Anixa Biosciences stated, "While this new development may be disappointing to shareholders, we have decided that we want to go into the clinic with the best possible therapy. CAR-T technology has not worked in a clinically meaningful way for solid tumors. Making this change would result in a radically superior therapy and give us a dramatically greater chance of success against ovarian cancer, a solid tumor."
"These decisions are based on scientific developments. Our technology is the most cutting-edge science and as R&D results mandate, and for the welfare of patients, we must provide the best possible chance of success. The Anixa and Moffitt teams will strive to get into the clinic as soon as possible with the best possible therapy," commented Dr. Conejo-Garcia.
Dr. Robert Wenham, Chair of the Department of Gynecologic Oncology at Moffitt, and the investigator who will be leading the clinical trial, noted, "Mortality rates from ovarian cancer have not changed for decades, with most women relapsing after initial therapy. Based on the pre-clinical data and promise of this CAR-T therapy, I look forward to launching the clinical trial with the more optimized therapy in order to give our patients the best chance of a successful outcome."
US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology
PR Newswire PR Newswire•April 17, 2019
SAN JOSE, Calif., April 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No. 10,259,855. This is the first patent covering Anixa's CAR-T cancer treatment technology.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Perales-Puchalt is a Senior Postdoctoral Fellow in The Wistar Institute's Vaccine & Immunotherapy Center. The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.
Dr. Amit Kumar, Anixa's Chairman, President and CEO, stated, "The claims of this patent were allowed in January of this year as noted in a previous announcement, and we are pleased that this key patent has now issued. Those interested in reviewing the patent can now read the content." Dr. Kumar continued, "This technology takes advantage of specific hormone–hormone receptor biology to address malignancies and may hold promise to be the one of the first successful CAR-T therapies against solid tumors. While our initial focus is the treatment of ovarian cancer, the technology covered by the patent is broad and may also be effective in treating other solid tumors by exploiting an anti-angiogenesis mechanism of action. Anixa and its research and clinical development partner, the Moffitt Cancer Center, hope to file an IND application for this therapy later this year.
US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology
PR Newswire PR Newswire•April 17, 2019
SAN JOSE, Calif., April 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No. 10,259,855. This is the first patent covering Anixa's CAR-T cancer treatment technology.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Perales-Puchalt is a Senior Postdoctoral Fellow in The Wistar Institute's Vaccine & Immunotherapy Center. The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.
Dr. Amit Kumar, Anixa's Chairman, President and CEO, stated, "The claims of this patent were allowed in January of this year as noted in a previous announcement, and we are pleased that this key patent has now issued. Those interested in reviewing the patent can now read the content." Dr. Kumar continued, "This technology takes advantage of specific hormone–hormone receptor biology to address malignancies and may hold promise to be the one of the first successful CAR-T therapies against solid tumors. While our initial focus is the treatment of ovarian cancer, the technology covered by the patent is broad and may also be effective in treating other solid tumors by exploiting an anti-angiogenesis mechanism of action. Anixa and its research and clinical development partner, the Moffitt Cancer Center, hope to file an IND application for this therapy later this year.
Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast Cancer at AACR Conference
PR Newswire PR NewswireDecember 3, 2018
SAN JOSE, Calif., Dec. 3, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study focusing on early detection of breast cancer, utilizing Cchek™, its artificial intelligence (AI) driven cancer detection technology, at the American Association of Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy. The conference is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to address cancer. The conference was held November 27–30, 2018 in Miami Beach, Florida.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
Anixa presented data demonstrating the ability of Cchek™ to identify the presence of early stage breast cancer in a subject by using its AI technology to analyze a simple blood draw. The Cchek™ technology demonstrated a sensitivity of 89.3% when detecting early stage breast cancer (Stage I or II) and a specificity (the ability to correctly identify healthy subjects) of 94.7% when used to test blinded samples. Furthermore, Cchek™ was also able to detect the early stages of breast cancer (Stage 0) in subjects with biopsy-confirmed ductal carcinoma in situ (DCIS), a type of pre-cancerous/non-invasive breast lesion that often leads to invasive breast cancer, with 72% sensitivity. The presentation is available on Anixa's website, or it may be requested by sending an email to AACR-TII-2018@anixa.com and including your name, title, and contact information.
"We are pleased to have made our presentation titled, Combining the immunophenotyping of MDSCs and lymphocytes with artificial intelligence (AI) to predict early stage breast cancer, at the AACR Tumor Immunology and Immunotherapy conference. This data was focused on using our Cchek™ technology to detect breast cancer in its early stages, primarily stage I and II when the cancer is more easily treated. The majority of screening technologies currently used for breast cancer detection, such as mammography, have the ability to detect later stage breast malignancies rather successfully but have shown difficulty with earlier stages. A major challenge with mammography is the large number of false positives resulting in overtreatment and many unnecessary biopsies," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. "As our study continues, we hope to enable a better approach for identifying breast cancer as early as possible including even when a non-invasive breast cancer lesion is present, such as in the case of DCIS. We have previously announced that our initial commercial focus is on a prostate cancer test for which we will be meeting with the USFDA on December 17, 2018. We recently presented our latest prostate cancer data at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC)," added Dr. Kumar.
Anixa Biosciences Releases Data Presented at AACR Artificial Intelligence Conference $ANIX
https://seekingalpha.com/pr/17303096
Can you paste alert? Thx
ITUS Corp. (ITUS) Stock: A Disruptive Force In Cancer Diagnostics And Immunotherapy
ACCESSWIRE ACCESSWIREJune 12, 2018
CORAL SPRINGS, FL / ACCESSWIRE / June 12, 2018 / Cancer is a devastating illness that affects a large population of patients in the United States. In fact, it is estimated by the National Cancer Institute that in the year 2018 alone, 1.73535 million patients will be diagnosed with cancer and 609,640 Americans will succumb to the ailment. However, thanks to incredible advances in the areas of cancer diagnostics and immunotherapy, the mortality rate may change drastically ahead. At the helm of innovation in the cancer diagnostics and immunotherapy markets, we find ITUS Corp. (NASDAQ: ITUS).
What Is ITUS?
Founded in 1982, but repositioned a couple of years ago, ITUS Corp. is no stranger to the biotechnology space. The company's primary focus is on both speeding up the process and relieving the invasiveness associated with cancer diagnostics, and treating cancer with innovative treatment options. Currently, the company is working on the development of two primary products, the first, CCheckTM, is a liquid biopsy diagnostic tool for the early detection of cancer. The second of these products, a CAR-T technology, is being developed for the treatment of cancer.
Looking Into Diagnostics
In the world of medicine and diagnostics, nothing is really a perfect science. In medicine, we know that medications come with side effects. It's part of the process. On the diagnostics end of the spectrum, there are also challenges. In fact, for a cancer diagnostics screen to be a success, it must have four things:
Reliability – False positives are commonly seen in cancer diagnostics. In fact, widely accepted diagnostic tests like the mammogram for breast cancer, PSA test for prostate cancer and low dose CT for lung cancer all have faced reliability issues.
Accuracy – You may be surprised to find that some cancer screenings, like the PSA screening, are known to have poor accuracy issues, failing to detect when cancer is present.
Easy – Often cancer screenings are not easy. As a result, many are not used. Screening options like colonoscopies are invasive and can be difficult for the patient.
Affordability – At the end of the day, if the patient, or our healthcare system, cannot afford the diagnostic test, chances are that they won't get it. However, there are high expenses involved in most diagnostic options.
These are the problems that ITUS is working to solve with their liquid biopsy cancer screening, known as CCheckTM. In fact, this diagnostic tool checks all of the boxes:
Reliability – Preliminary data surrounding the CCheckTM liquid biopsy are incredible. In fact, when it comes to reliability, or how good a test is at distinguishing cancer patients from healthy patients, CCheckTM scored a 91%. This is overwhelmingly impressive when compared to LDCT at 73%, PSA at 63% and Mammogram at 75%.
Accuracy – Accuracy measures, or how good a test is at detecting cancer, were also off the charts at 91%. While LDCT screenings have an accuracy of 93%, PSA only scores 35%, mammogram screenings only score 68%.
Easy – Unlike various invasive cancer screenings, CCheckTM is incredibly easy. In fact, the screening is a liquid biopsy, which means that it is nothing more than a simple blood test, making it more comfortable for patients to get screened.
Affordability – The CCheckTM diagnostic screening is incredibly affordable in comparison to other options.
ITUS Brings Artificial Intelligence To Oncology
Artificial intelligence (AI) is being used in just about every facet of our lives. Advertisers use AI to find the right audience at the right price; engineers at Google, Apple, and others are using AI to drive autonomous vehicles; and consumers are using AI to do everything from turn on the lights in their homes to tell them what's in their refrigerator when they are out grocery shopping. The reality is that the use of AI is limitless, and ITUS saw an opportunity in that fact.
The technology that powers the CCheckTM diagnostic screening is known as a Neural Network, or NN. NN is a proprietary AI system that is specifically focused on the recognition of complex patterns. In fact, NN has been trained through AI and machine learning to distinguish the difference between the immunological responses of cancer patients and of healthy patients. In order to do so, NN relies on up to 15 quantitative parameters on over 40,000 cells for each patient, when analyzing test results.
Interestingly enough, ITUS has already made NN overwhelmingly reliable and accurate, with accuracy and reliability rates at 91%. However, due to the machine learning capabilities of the AI system, as it processes more and more samples, the system will learn how to make even more accurate and reliable distinctions. Considering that the NN system is not subject to human error or bias, it is believed that it may lead to the most accurate results in the diagnosis of cancer.
CCheckTM Has Been Validated With 15 Cancer Types
The accuracy and reliability of the CCheckTM system, thanks to the NN AI, is accurate among multiple different types of cancer. In fact, to date, it has been validated in breast, lung, colon, prostate, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, and vulvar cancers as well as melanoma, osteosarcoma, leiomyosarcoma and lipsarcoma.
Cancer Treatment
As mentioned above, cancer diagnostics isn't the only area of business in which ITUS operations. The company is also involved in an innovative solution to treat the ailment. The solution, known as chimeric antigen receptor T-cell, or CAR-T, therapy is a relatively new form of immunotherapy that has become a topic of interest among the medical community and the investing community alike.
Without getting too technical, CAR-T therapy uses T-cells, a key factor in your immune system to fight cancer. By re-programming T-cells to attack cancer cells that carry specific proteins, CAR-T therapy is a highly-targeted option in the fight against cancer.
At the moment, CAR-T has shown some serious promise, but only in a few types of cancer. These include liquid cancer types like lymphoma and blood cancers. That's because these liquid tumors display ] a protein that is relatively easy to target by the re-programmed T-cells. However, solid tumors are a very different cancer.
However, ITUS is acting on newly discovered information that may allow the company to use CAR-T therapy to address solid tumors. Some forms of solid tumors are made of cancer cells that have an exclusive protein on the cell surface as well. ITUS believes that by programming T-cells to attack the cells carrying these specific proteins, it may be able to use CAR-T therapy to combat solid tumors.
If ITUS and its collaborators at the Moffitt Cancer Center are the first to show their CAR-T technology works on solid tumors, it could be worth billions, especially since other companies that have demonstrated efficacy in select tumor types have been recently acquired for billions.
The Catalyst Is Around The Corner
When it comes to the treatment of cancer, ITUS has a catalyst that's just around the corner. In fact, ITUS is in the process of launching a CAR-T drug development program to fight against Ovarian Cancer. Late last year, the company announced that it has entered into an exclusive worldwide license agreement with The Wistar Institute for a CAR-T technology that's aimed initially at treating ovarian cancer. Shortly thereafter, ITUS entered a cooperative research and development agreement (CRADA) with the Moffit Cancer Center to develop the therapy. Of course, over time the company plans on targeting other solid tumor cancers as well.
CAR-T Is Incredibly Valuable
At the moment, all eyes are on CAR-T treatments as scientists work to break the line between liquid and solid tumor treatment. In fact, recently, there have been two massive acquisitions surrounding CAR-T. In fact, Celgene (CELG) recently acquired Juno Therapeutics for $9 billion. Also, Kite Pharma, Inc, was recently acquired by Gilead Sciences (GILD) for $12 billion. Both of these acquisitions had to do with CAR-T technologies.
ITUS Is Trusted By Several Collaborators
As a validation of their efforts on both the diagnostic and the treatment arms of the company, ITUS is currently in various collaborations with some of the world's most renowned leaders in oncology. Some of these names include The Wistar Institute, MD Anderson Cancer Network, Virtua, Moffitt Cancer Center, the University of Pennsylvania Abramson Cancer Center, and Delaware Valley Urology.
The Bottom Line
The bottom line here is that both, the liquid biopsy and the CAR-T spaces are getting quite a bit of spotlight. This is not only for their abilities in their respective spaces but due to the investment interest that surrounds them. At the end of the day, through the decision to move forward with these types of technologies, ITUS has set a solid foundation for growth in two industries with massive untapped potential!
Disclaimer- CNA Finance is NOT an Investment Advisor. Our goal is to bring both news and under discovered stocks to the attention to investors to assist in making smart decisions in the market. CNA Finance is a for profit company. That profit is generated through three (3) different types of relationships. First and foremost, we work with pay per click and CPM advertisers on banners. We also have affiliate relationships with various companies where we earn a portion of the sales we refer. Finally, we may have relationships with some of the companies or IR firms that represent companies mentioned within our works in which we are compensated in cash and or stock for consulting, investor relations, and Press Release services. Invictus Resources paid CNA Finance $6,000 for research and writing services as well as other digital investor relations tasks provided to ITUS Corp. Therefore, while we do everything in our power to provide true, well-researched, and well-thought out opinions, in some instances, a potential conflict of interest may exist. CNA Finance encourages all investors to seek professional advice before making any investment decision.
SOURCE: CNA Finance, LLC
I see not much chatter on this stock, looks like 40 days ago your buy post proved out good. I was in there with you riped it out at 5.1/8. I was thinking getting back in at a 2 handle depending where the raise ends up. DO you still play ITUS ?
Looks like this is going to fill a gap at $2.65 area.
Chart cooling off
any details on false negatives and false positives
Yep it was a sell on the news PR.
Crazy that people are selling that low.
ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium
SAN JOSE, Calif., Jan. 29, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it presented positive data from its early cancer detection technology on January 26th at the American Society of Clinical Oncology-Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-oncology Symposium in San Francisco, CA.
ITUS Logo (PRNewsfoto/ITUS Corporation)
The poster presentation titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," presented the latest data from our ongoing study. Our technology combines the analysis of myeloid-derived suppressor cells (MDSCs) and other subsets of white blood cells with Artificial Intelligence (AI), specifically a neural network (NN), to monitor the patient's immune system.
Statistics clearly show that when cancer is detected early (Stage I or II), the chances of long term survival are often greater than 95%, or even 100% in some cases. However, if the cancer is detected late (Stage III or IV), the probability of long term survival declines to levels as low as 10%. Understandably, there has been tremendous interest from the scientific and investment community in the development of techniques for early cancer detection. ITUS, one of the few publicly traded companies operating in this arena, utilizes a proprietary technique to monitor changes in a patient's immune system driven by the presence of a tumor.
Studies over the past decade have demonstrated that there is a dynamic interaction between a patient's immune system and the existence of a tumor. This interaction results in subtle changes in the immune system that can be measured by monitoring and counting circulating white blood cells using a common laboratory technique known as flow cytometry. However, simply counting the specific cells is not sufficient to distinguish, with high accuracy, the difference between a tumor-bearing patient and a healthy individual. By implementing a NN to evaluate the subtle changes and patterns found within the immune system, we are able to achieve extremely high sensitivity and specificity, which are measures of accuracy of the test.
The results of this current study augment data from our first cohort, which was released in December of 2016. In the previous study, we reported sensitivity of 92% and specificity of 92%. In this study, we report a sensitivity of 89% and a specificity of 95%. This minor decrease in sensitivity in our current study was found to be within the margin of error and possibly reflects the inclusion of more early stage cancer patients. All cancer patients were biopsy-verified with all clinical stages (I - IV) included. The Area Under the Receiver Operating Characteristic Curve (AUROC), a measure of accuracy, was 0.97. AUROC values near 0.50 are poor, while a value greater than 0.90 is considered exceptional.
Additionally, one of the most beneficial attributes of artificial intelligence and neural networks is their ability to continuously learn and improve over time in answering the question asked of them. This means that as we add more data, we would expect to improve the performance even more.
The total number of patients in this study was 163, which included 81 cancer patients and 82 healthy donors. The patient blood samples were provided by our collaborators, including the MD Anderson Cancer Center at Cooper, The University of Pennsylvania-Abramson Cancer Center, Virtua Hospital Group, Delaware Valley Urology, and the Wistar Institute. The majority of patient samples collected for this study were from breast cancer and prostate cancer patients, but several other types were also included. Previously, we have reported that our technology has worked successfully with 15 different types of tumors. With the additional cancers included in this study, we have now demonstrated that our technology works with 20 types of cancer from solid tumors. The list of tumor types evaluated by our technology to date is as follows:
1.Breast
2.Prostate
3.Lung
4.Colon
5.Pancreatic
6.Melanoma
7.Ovarian
8.Liver
9.Bladder
10.Cervical
11.Endometrial/Uterine
12.Gastric
13.Head and neck
14.Testicular
15.Thyroid
16.Osteosarcoma (bone cancer)
17.Leiomyosarcoma (cancer of the soft tissue)
18.Liposarcoma (cancer of the connective tissue)
19.Vulvar
20.Appendiceal
Dr. Amit Kumar, ITUS Corporation's President and Chief Executive Officer, stated, "We are pleased to present the latest data from our studies. While these studies were done un-blinded, and more data needs to be obtained, we are extremely pleased with the performance. As a scientist, there are two conclusions that I can make. First, it is clearly the case that our proprietary artificial intelligence application is better at making the calls than the best and most experienced scientists or physicians. The ability of the NN to be trained and analyze the data is extraordinary. Second, because our technology monitors the response of the immune system to the existence of a tumor, we feel this technique will be able to identify any individual with cancer regardless of the tumor type. The immune system undergoes changes regardless of the location of the tumor, hence the patterns indicative of a tumor should exist regardless of the type. Such an assertion is supported by the fact that we have been able to identify the presence of cancer in patients with 20 different tumor types, although in some cases we only tested a small number of samples."
Dr. Kumar continued, "We are looking forward to publishing this data and also sharing data from other studies we are in the midst of completing. We are also pleased that our latest patent claims were recently allowed enabling us to properly protect our technology. To our knowledge, we are the only company that is developing a liquid biopsy diagnostic that incorporates flow cytometry data and artificial intelligence. While it is too early to establish an eventual price for our test, we feel confident that we will be able to provide a price of less than $200 dollars."
To receive a copy of the poster presentation, please send your request to ASCO-SITC-2018@ITUScorp.com and include your name, title, and contact information.
ASCO-SITC
The ASCO-SITC Clinical Immuno-Oncology Symposium (https://immunosym.org) is a three-day meeting focused on clinical and translational research in immuno-oncology and the implications for clinical care.
ASCO (www.asco.org) was founded in 1964 and is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.
SITC (www.sitcancer.org) was found in 1984 and is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the CchekTM platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.ITUScorp.com.
ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium
PR Newswire PR Newswire•January 29, 2018
SAN JOSE, Calif., Jan. 29, 2018 /PRNewswire/ -- ITUS Corporation (ITUS), today announced that it presented positive data from its early cancer detection technology on January 26th at the American Society of Clinical Oncology-Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-oncology Symposium in San Francisco, CA.
ITUS Logo (PRNewsfoto/ITUS Corporation)
ITUS Logo (PRNewsfoto/ITUS Corporation)
More
The poster presentation titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," presented the latest data from our ongoing study. Our technology combines the analysis of myeloid-derived suppressor cells (MDSCs) and other subsets of white blood cells with Artificial Intelligence (AI), specifically a neural network (NN), to monitor the patient's immune system.
Statistics clearly show that when cancer is detected early (Stage I or II), the chances of long term survival are often greater than 95%, or even 100% in some cases. However, if the cancer is detected late (Stage III or IV), the probability of long term survival declines to levels as low as 10%. Understandably, there has been tremendous interest from the scientific and investment community in the development of techniques for early cancer detection. ITUS, one of the few publicly traded companies operating in this arena, utilizes a proprietary technique to monitor changes in a patient's immune system driven by the presence of a tumor.
Studies over the past decade have demonstrated that there is a dynamic interaction between a patient's immune system and the existence of a tumor. This interaction results in subtle changes in the immune system that can be measured by monitoring and counting circulating white blood cells using a common laboratory technique known as flow cytometry. However, simply counting the specific cells is not sufficient to distinguish, with high accuracy, the difference between a tumor-bearing patient and a healthy individual. By implementing a NN to evaluate the subtle changes and patterns found within the immune system, we are able to achieve extremely high sensitivity and specificity, which are measures of accuracy of the test.
The results of this current study augment data from our first cohort, which was released in December of 2016. In the previous study, we reported sensitivity of 92% and specificity of 92%. In this study, we report a sensitivity of 89% and a specificity of 95%. This minor decrease in sensitivity in our current study was found to be within the margin of error and possibly reflects the inclusion of more early stage cancer patients. All cancer patients were biopsy-verified with all clinical stages (I - IV) included. The Area Under the Receiver Operating Characteristic Curve (AUROC), a measure of accuracy, was 0.97. AUROC values near 0.50 are poor, while a value greater than 0.90 is considered exceptional.
Additionally, one of the most beneficial attributes of artificial intelligence and neural networks is their ability to continuously learn and improve over time in answering the question asked of them. This means that as we add more data, we would expect to improve the performance even more.
The total number of patients in this study was 163, which included 81 cancer patients and 82 healthy donors. The patient blood samples were provided by our collaborators, including the MD Anderson Cancer Center at Cooper, The University of Pennsylvania-Abramson Cancer Center, Virtua Hospital Group, Delaware Valley Urology, and the Wistar Institute. The majority of patient samples collected for this study were from breast cancer and prostate cancer patients, but several other types were also included. Previously, we have reported that our technology has worked successfully with 15 different types of tumors. With the additional cancers included in this study, we have now demonstrated that our technology works with 20 types of cancer from solid tumors. The list of tumor types evaluated by our technology to date is as follows:
Breast
Prostate
Lung
Colon
Pancreatic
Melanoma
Ovarian
Liver
Bladder
Cervical
Endometrial/Uterine
Gastric
Head and neck
Testicular
Thyroid
Osteosarcoma (bone cancer)
Leiomyosarcoma (cancer of the soft tissue)
Liposarcoma (cancer of the connective tissue)
Vulvar
Appendiceal
Dr. Amit Kumar, ITUS Corporation's President and Chief Executive Officer, stated, "We are pleased to present the latest data from our studies. While these studies were done un-blinded, and more data needs to be obtained, we are extremely pleased with the performance. As a scientist, there are two conclusions that I can make. First, it is clearly the case that our proprietary artificial intelligence application is better at making the calls than the best and most experienced scientists or physicians. The ability of the NN to be trained and analyze the data is extraordinary. Second, because our technology monitors the response of the immune system to the existence of a tumor, we feel this technique will be able to identify any individual with cancer regardless of the tumor type. The immune system undergoes changes regardless of the location of the tumor, hence the patterns indicative of a tumor should exist regardless of the type. Such an assertion is supported by the fact that we have been able to identify the presence of cancer in patients with 20 different tumor types, although in some cases we only tested a small number of samples."
Dr. Kumar continued, "We are looking forward to publishing this data and also sharing data from other studies we are in the midst of completing. We are also pleased that our latest patent claims were recently allowed enabling us to properly protect our technology. To our knowledge, we are the only company that is developing a liquid biopsy diagnostic that incorporates flow cytometry data and artificial intelligence. While it is too early to establish an eventual price for our test, we feel confident that we will be able to provide a price of less than $200 dollars."
To receive a copy of the poster presentation, please send your request to ASCO-SITC-2018@ITUScorp.com and include your name, title, and contact information.
ASCO-SITC
The ASCO-SITC Clinical Immuno-Oncology Symposium (https://immunosym.org) is a three-day meeting focused on clinical and translational research in immuno-oncology and the implications for clinical care.
ASCO (www.asco.org) was founded in 1964 and is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.
SITC (www.sitcancer.org) was found in 1984 and is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the CchekTM platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.ITUScorp.com.
Imo long term this will be huge!!
Followers
|
42
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
720
|
Created
|
06/05/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |